Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Challenges recruiting to a proof-of-concept pharmaceutical trial for a rare disease: the trigeminal neuralgia experience
- J. Zakrzewska, J. Palmer, +8 authors G. Cruccu
- Medicine
- Trials
- 27 December 2018
BackgroundThis study aimed to describe recruitment challenges encountered during a phase IIa study of vixotrigine, a state and use-dependent Nav1.7 channel blocker, in individuals with trigeminal… Expand
Evaluation of the Pharmacokinetic Interaction Between the Voltage‐ and Use‐Dependent Nav1.7 Channel Blocker Vixotrigine and Carbamazepine in Healthy Volunteers
- J. Dunbar, Mark Versavel, +6 authors Himanshu Naik
- Medicine
- Clinical pharmacology in drug development
- 1 January 2020
Vixotrigine is a voltage‐ and use‐dependent Nav1.7 channel blocker under investigation for the treatment of peripheral neuropathic pain conditions, including trigeminal neuralgia. Vixotrigine is… Expand
(386) A novel proof of concept, placebo controlled, randomised withdrawal study, demonstrating the safety and efficacy of CNV1014802 in patients with trigeminal neuralgia
- Simon Tate, J. Palmer, +5 authors J. Zakrzewska
- Medicine
- 1 April 2015
(387) A novel proof of concept, randomized, double blind, cross-over study demonstrating the safety and efficacy of CNV1014802 in subjects with neuropathic pain from lumbosacral radiculopathy
- Simon Tate, J. Palmer, Valerie Morisset, Gerard Mp Giblin, B. Bragee, K. Gunn
- Medicine
- 1 April 2015
Peripheral inflammation produces a tonic EP1 receptor-mediated modulation of synaptic inputs to substantia gelatinosa neurones of the rat
- C. Davies, G. Giblin, S. Lappin, Valerie Morisset, A. Randall
- Chemistry
- 2004
Discovery of Vixotrigine: A Novel Use-Dependent Sodium Channel Blocker for the Treatment of Trigeminal Neuralgia.
- D. Witty, Giuseppe Alvaro, +11 authors Himanshu Naik
- Medicine
- ACS medicinal chemistry letters
- 16 July 2020
Drugs that block voltage-gated sodium channels (NaVs) have utility in treating conditions including pain, epilepsy, and cardiac arrhythmias and as anesthetics (Lancet Neurol.20109413424; Expert Opin.… Expand
Spinal vanilloid receptor-1 (TRPV1) becomes tonically active following peripheral inflammation
- Martin J. Gunthorpe, S. Lappin, Valerie Morisset, A. Randall
- Medicine
- 2004
Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial. Lancet Neurol 2017;
- Prof Joanna M Zakrzewska, J. Palmer, +13 authors Simon Tate
- 2017
1 ACCEPTED AUTHOR VERSION OF ARTICLE: Zakrzewska JM, Palmer J, Morisset V, Giblin GMP, Obermann M, Ettlin DA, Cruccu G, Bendtsen L, Estacion M, Derjean D, Waxman SG, Layton G, Gunn K, Tate S. Safety… Expand